The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes

Hashimoto, Yoshitaka; Osaka, Takafumi; Fukuda, Takuya; Tanaka, Muhei; Yamazaki, Masahiro; Fukui, Michiaki

doi:10.1507/endocrj.ej16-0124

Cited by 65 publications

(71 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fourth, heterogeneity was not negligible when pooled OR of sarcopenia for NAFLD occurrence. In terms of our conjecture, the study by Hong et al [23] or the study by Hashimoto et al [28] enrolling unrepresentative subjects should be responsible for the heterogeneity except partly attributing to different methods of identifying sarcopenia and NAFLD and different underlying population. Nevertheless, in sensitivity analyses, respectively, omitting these 2 studies, pooled ORs for NAFLD were not obviously affected, indicating robustness of the initial analysis.…”

Section: Discussionmentioning

confidence: 76%

“…At this stage, some of them did not define sarcopenia clearly, without available OR, no compatator, or were animal experiment or case report, letters, and reviews. Ultimately, 6 studies enrolling 19,024 participants met the eligible criteria strictly and were included in the final analysis [23][24][25][26][27][28].…”

Section: Search Results and Description Of Included Studiesmentioning

confidence: 99%

“…Finally, considering moderate heterogeneity in meta-analysis pooling OR for NAFLD, we performed sensitivity analyses by sequentially removing 1 study in each cycle to assess its effect on results stability by STATA 12.0 software. Specifically, we respectively deleted the study by Hong et al [23] and the study by Hashimoto et al [28], which might be sources of heterogeneity to observe the change of estimated pooled results in Review Manager 5.3. It should be noted that p values of < 0.05 was deemed to be statistically significant on the process of all data analyses.…”

Section: Discussionmentioning

confidence: 99%

“…In Figure 3, sensitivity analysis indicated that the OR of each included study was within the confidence interval of the total effect estimates and the estimated pooled results did not show significant changes in direction [28].…”

Section: Sensitivity Analysismentioning

confidence: 96%

“…Moreover, given that the subjects Hong et al [23] enrolled were not only with sarcopenia but also accompanied with obesity, the study by Hashimoto et al [28] only reported the results in men with type 2 diabetes; the above 2 studies that included the unrepresentative population should be responsible for the heterogeneity.…”

Section: Sources Of Heterogeneitymentioning

confidence: 99%

See 4 more Smart Citations

Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis

Pan

Han

Zou

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Backgrounds and Aims: Previous studies have investigated that sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, and fibrosis in NAFLD. The study aims to investigate the risk for NAFLD, especially NAFLD-related significant fibrosis among subjects with sarcopenia. Methods: We searched electronic databases until 30, September 2017 and reviewed literature extensively. Effect estimates were pooled using random effect models regarding the risk for NAFLD and fixed effect models concerning the risk for significant fibrosis among sarcopenia patients. Sensitivity analysis was performed for the risk of NAFLD. Results: We identified 6 studies. Our results showed that subjects with sarcopenia exhibited an increased risk for NAFLD compared to those without sarcopenia (OR 1.29, 95% CI 1.12–1.49) with heterogeneity among the individual studies (I² = 61%). And the risk for NAFLD-related significant fibrosis appeared to be more pronounced in sarcopenia patients (OR 1.57, 95% CI 1.29–1.90) with an I² of 0%. Sensitivity analysis revealed that neither the direction nor the magnitude of the estimated pooled results for NAFLD was obviously affected. Furthermore, the pooled ORs were both close to initial analysis when omitting the study by Hong et al. [Hepatology 2014; 59: 1772–1778] (OR 1.24, 95% CI 1.11–1.39, I² = 47%) or by Hashimoto et al. [Endocr J 2016; 63: 877–884] (OR 1.33, 95% CI 1.11–1.59, I² = 67%), which were considered sources of heterogeneity. Conclusions: Our analysis demonstrated that sarcopenia served not only as a risk factor for the onset of NAFLD but also related to the progression of NAFLD-related significant fibrosis.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Search Results and Description Of Included Studiesmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Sensitivity Analysismentioning

confidence: 96%

Section: Sources Of Heterogeneitymentioning

confidence: 99%

See 3 more Smart Citations

Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis

Pan

Han

Zou

et al. 2018

Dig Dis

View full text Add to dashboard Cite

show abstract

Brazilian green propolis improves gut microbiota dysbiosis and protects against sarcopenic obesity

Okamura

Hamaguchi

Bamba

et al. 2022

J cachexia sarcopenia muscle

Self Cite

View full text Add to dashboard Cite

Introduction Brazilian green propolis is an important honeybee product that is considered beneficial for health. Here, we examined the therapeutic potential of dietary supplementation with propolis against sarcopenic obesity using Db/Db mice. Methods Db/m mice fed a normal diet alone and Db/Db mice fed normal diet alone, or supplemented with different amounts of propolis (0.08, 0.4 and 2%), were examined for effects on sarcopenic obesity. Results Propolis improved the glucose tolerance (P < 0.001), increased the grip strength (P < 0.001) and the weight of soleus (P = 0.006) and plantaris muscles (P = 0.008). Moreover, propolis improved the non-alcoholic fatty liver disease activity score (P < 0.001) and decreased the expression of genes related to inflammation, liver fibrosis and fatty acid metabolism. Propolis decreased the accumulation of saturated fatty acids in the liver and increased their excretion in faeces. With regard to the innate immunity, propolis decreased the ratio of M1 macrophages (P = 0.008) and Type 1 and 3 innate lymphoid cells to CD45-positive cells (P < 0.001) and increased the ratio of M2 macrophages (P = 0.002) and ILC2s (P = 0.007) in the liver. Additionally, propolis decreased the expression of genes related to muscle atrophy and inflammation and the concentration of saturated fatty acids in the soleus muscle. 16S rRNA phylogenetic sequencing revealed that propolis increased the Bacteroidetes/Firmicutes ratio, and the abundance of Butyricicoccus and Acetivibrio genera. Gut microbiota related to the pentose phosphatase pathway and glycerolipid metabolism was more prevalent after the administration of propolis. Conclusions This is the first study to demonstrate that propolis can improve sarcopenic obesity by improving dysbiosis due to overeating and provides new insights into diet-microbiota interactions during sarcopenic obesity.

show abstract

Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved

Song

Xia

Liu

et al. 2018

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes

Cited by 65 publications

References 53 publications

Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis

Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis

Brazilian green propolis improves gut microbiota dysbiosis and protects against sarcopenic obesity

Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved

Contact Info

Product

Resources

About